Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Trisomy 8, a cytogenetic abnormality in Myelodysplastic Syndromes, is constitutional or not?

  • Saumell i Tutusaus, Sílvia
  • Solé Ristol, Francesc
  • Arenillas, Leonor|||0000-0002-9020-8766
  • Montoro Gómez, Maria Julia|||0000-0001-9532-7417
  • Valcárcel, David|||0000-0002-8747-078X
  • Pedro, Carme
  • Sanzo, Carmen
  • Luño, Elisa
  • Giménez, Teresa
  • Arnan, Montserrat
  • Pomares, Helena
  • Paz, Raquel de
  • Arrizabalaga, Beatriz
  • Jerez, Andrés|||0000-0002-2079-6638
  • Martínez, Ana B.
  • Sánchez-Castro, Judith
  • Rodríguez-Gambarte, Juan D.
  • Raya, José M.|||0000-0002-7202-5712
  • Ríos, Eduardo
  • Rodríguez-Rivera, María
  • Espinet i Solà, Blanca
  • Florensa Brichs, Maria Lourdes
Isolated trisomy 8 is not considered presumptive evidence of myelodysplastic syndrome (MDS) in cases without minimal morphological criteria. One reason given is that trisomy 8 (+8) can be found as a constitutional mosaicism (cT8M). We tried to clarify the incidence of cT8M in myeloid neoplasms, specifically in MDS, and the diagnostic value of isolated +8 in MDS. Twenty-two MDS and 10 other myeloid neoplasms carrying +8 were studied. Trisomy 8 was determined in peripheral blood by conventional cytogenetics (CC) and on granulocytes, CD3+ lymphocytes and oral mucosa cells by fluorescence in situ hybridization (FISH). In peripheral blood CC, +8 was seen in 4/32 patients. By FISH, only one patient with chronic myelomonocytic leukemia showed +8 in all cell samples and was interpreted as a cT8M. In our series +8 was acquired in all MDS. Probably, once discarded cT8M by FISH from CD3+ lymphocytes and non-hematological cells, +8 should be considered with enough evidence to MDS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes

  • McGraw, Kathy L.
  • Cluzeau, Thomas
  • Sallman, David A.
  • Basiorka, Ashley A.
  • Irvine, Brittany A.
  • Ling, Zhang
  • Epling-Burnette, P. K.
  • Rollison, Dana E.
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Sokol, Lubomir
  • Sole, F.|||0000-0002-3251-2161
  • Maciejewski, Jaroslaw|||0000-0002-6837-4346
  • List, Alan F.
Abstract:P53 is a key regulator of many cellular processes and is negatively regulated by the human homolog of murine double minute-2 (MDM2) E3 ubiquitin ligase. Single nucleotide polymorphisms (SNPs) of either gene alone, and in combination, are linked to cancer susceptibility, disease progression, and therapy response. We analyzed the interaction of TP53 R72P and MDM2 SNP309 SNPs in relationship to outcome in patients with myelodysplastic syndromes (MDS). Sanger sequencing was performed on DNA isolated from 208 MDS cases. Utilizing a novel functional SNP scoring system ranging from +2 to -2 based on predicted p53 activity, we found statistically significant differences in overall survival (OS) (p = 0.02) and progression-free survival (PFS) (p = 0.02) in non-del(5q) MDS patients with low functional scores. In univariate analysis, only IPSS and the functional SNP score predicted OS and PFS in non-del(5q) patients. In multivariate analysis, the functional SNP score was independent of IPSS for OS and PFS. These data underscore the importance of TP53 R72P and MDM2 SNP309 SNPs in MDS, and provide a novel scoring system independent of IPSS that is predictive for disease outcome.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features

  • Palomo Sanchís, Laura|||0000-0003-3176-6271
  • García, Olga
  • Arnan, Montserrat
  • Xicoy, Blanca|||0000-0002-0295-1307
  • Fuster García, Francisco|||0000-0002-2528-6143
  • Cabezón, Marta|||0000-0001-5122-7481
  • Coll, Rosa|||0000-0003-0560-1254
  • Ademà, Vera|||0000-0001-6051-4378
  • Grau Cat, Javier
  • Jiménez, Maria-José
  • Pomares, Helena
  • Marcé, Silvia|||0000-0001-9128-6822
  • Mallo, Maria del Mar|||0000-0001-7741-498X
  • Millá, Fuensanta
  • Alonso, Esther
  • Sureda, Anna|||0000-0002-1238-6970
  • Gallardo, David|||0000-0003-1615-4592
  • Feliu Frasnedo, Evarist|||0000-0001-5780-3136
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Sole, F.|||0000-0002-3251-2161
  • Zamora, Lurdes|||0000-0003-1713-7110
Clonal cytogenetic abnormalities are found in 20-30% of patients with chronic myelomonocytic leukemia (CMML), while gene mutations are present in.